Lazard Upgrades XenoPort (XNPT) to Buy
More News related to XNPT
- CORRECTING and REPLACING GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- XenoPort (XNPT) November volatility at 130, March at 84 into data
- XenoPort (XNPT) Posts Q3 Loss of $0.81, Misss Views
More News related to Upgrades
- S&P Revises Outlook on Sirius XM (SIRI) from Stable to Positive
- DA Davidson Upgrade Lifts Shares of Ameron (AMN) by ~9%
- Sterne Agee Upgrades TrustCo Bank Corp NY (TRST) to Neutral
- optionsXpress (OXPS) Upgraded Mid-Day at BofA, Stock Adds 3% to Today's Gains
- D.A. Davidson Upgrades Columbia Sportswear (COLM) to Buy
Lazard Capital upgrades XenoPort (Nasdaq: XNPT) from Hold to Buy.
XenoPort, Inc., a biopharmaceutical company, focuses on developing internally-discovered product candidates that utilize the body's natural nutrient transporter mechanisms.
Related Categories
UpgradesStocks Mentioned
-0.15Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
